Friday, June 2, 2023
No Result
View All Result
  • Media
Support Us
Macdonald-Laurier Institute
  • Home
  • About
    • Who We Are
    • Who Makes MLI Work
    • Tenth Anniversary
  • Experts
    • Experts Directory
    • In Memoriam
  • Issues
    • Domestic Policy Program
      • Agriculture and Agri-Food
      • Canada’s Political Tradition
      • Economic policy
      • Health Care
      • Innovation
      • Justice
      • Social issues
      • Telecoms
    • Energy Policy Program
      • Energy
      • Environment
    • Foreign Policy Program
      • Foreign Affairs
      • National Defence
      • National Security
    • Indigenous Affairs Program
  • Projects
    • The Great Energy Crisis
    • Centre for Advancing Canada’s Interests Abroad
    • Dragon at the Door
    • Canada and the Indo-Pacific Initiative
    • The Transatlantic Program
    • DisInfoWatch.org
    • An Intellectual Property Strategy for Canada
    • Competition Policy in Canada
    • Speak for Ourselves
    • Justice Report Card
    • COVID Misery Index
      • Provincial COVID Misery Index
      • Beyond Lockdown
      • COVID and after: A mandate for recovery
    • Indigenous Prosperity at a Crossroads
      • Aboriginal Canada and Natural Resources
    • Past Projects
      • The Eavesdropping Dragon: Huawei
      • Talkin’ in the Free World with Mariam Memarsadeghi
      • Munk Senior Fellows
      • A Mandate for Canada
      • Confederation Series
      • Fiscal Reform
      • The Canadian Century project
      • Fixing Canadian health care
      • Internal trade
      • From a mandate for change
      • Size of government in Canada
      • Straight Talk
      • Labour Market Report
      • Leading Economic Indicator
  • Events
    • Upcoming Events
    • Past Events
      • MLI Dinners
      • Great Canadian Debates
  • Latest News
  • Libraries
    • Inside Policy Magazine
      • Inside Policy Online
      • Inside Policy Back Issues
    • Papers
    • Commentary
    • Columns
    • Books
    • Video
    • Podcasts
  • Home
  • About
    • Who We Are
    • Who Makes MLI Work
    • Tenth Anniversary
  • Experts
    • Experts Directory
    • In Memoriam
  • Issues
    • Domestic Policy Program
      • Agriculture and Agri-Food
      • Canada’s Political Tradition
      • Economic policy
      • Health Care
      • Innovation
      • Justice
      • Social issues
      • Telecoms
    • Energy Policy Program
      • Energy
      • Environment
    • Foreign Policy Program
      • Foreign Affairs
      • National Defence
      • National Security
    • Indigenous Affairs Program
  • Projects
    • The Great Energy Crisis
    • Centre for Advancing Canada’s Interests Abroad
    • Dragon at the Door
    • Canada and the Indo-Pacific Initiative
    • The Transatlantic Program
    • DisInfoWatch.org
    • An Intellectual Property Strategy for Canada
    • Competition Policy in Canada
    • Speak for Ourselves
    • Justice Report Card
    • COVID Misery Index
      • Provincial COVID Misery Index
      • Beyond Lockdown
      • COVID and after: A mandate for recovery
    • Indigenous Prosperity at a Crossroads
      • Aboriginal Canada and Natural Resources
    • Past Projects
      • The Eavesdropping Dragon: Huawei
      • Talkin’ in the Free World with Mariam Memarsadeghi
      • Munk Senior Fellows
      • A Mandate for Canada
      • Confederation Series
      • Fiscal Reform
      • The Canadian Century project
      • Fixing Canadian health care
      • Internal trade
      • From a mandate for change
      • Size of government in Canada
      • Straight Talk
      • Labour Market Report
      • Leading Economic Indicator
  • Events
    • Upcoming Events
    • Past Events
      • MLI Dinners
      • Great Canadian Debates
  • Latest News
  • Libraries
    • Inside Policy Magazine
      • Inside Policy Online
      • Inside Policy Back Issues
    • Papers
    • Commentary
    • Columns
    • Books
    • Video
    • Podcasts
No Result
View All Result
Macdonald-Laurier Institute

Lower drug prices are a good thing. Canada’s approach to achieving them was not: Nigel Rawson in the Globe and Mail

Everyone would like drugs to be cheaper, but not at the expense of having pharmaceutical companies and their innovative medicines bypass Canada.

March 17, 2023
in Columns, Domestic Policy Program, Health, In the Media, Latest News, Nigel Rawson
Reading Time: 3 mins read
A A
The Patented Medicine Prices Review Board is selling Canadians a lemon: Nigel Rawson for Inside Policy

This article originally appeared in the Globe and Mail.

By Nigel Rawson, March 17, 2023

Over the past six years, the Patented Medicine Prices Review Board – Canada’s federal drug-price regulating agency – has sought to impose lower drug costs when new pharmaceuticals are introduced here. But the main achievement of that crusade is that fewer new medicines are now available to Canadians.

In order for medicines to hit the market here, manufacturers must submit them for regulatory authorization. Between 2006 and 2014, 80 per cent of new drugs submitted for regulatory approval in the United States or the European Union were also submitted for approval in Canada. But by 2020, that rate had fallen to just 44 per cent – a reflection of industry uncertainty.

That began in May, 2017, when then-health minister Jane Philpott set out to revise the PMPRB’s regulations. To justify the changes, she noted that prescription-drug spending represented 10 per cent of total health care spending in 1984, while in 2017 it was 14 per cent, where it remains today.

The plan was to replace two higher-price countries in the PMPRB’s 35-year-old price comparison test with six lower-price countries, implement untried “pharmacoeconomic” tests to determine prices, and require drug developers to report any confidential rebates negotiated with public and private insurers. The only measure that survived legal challenges, however, was the change in comparator countries. Without evidence of excessive pricing, the courts ruled in 2020 that the PMPRB is “not empowered to control or lower prices.”

In 2022, the PMPRB tried again. Instead of using its price-reference test with the new countries, the board invented new and complicated ways to try to severely reduce drug prices. Unlike the 2017 guidelines, the 2022 version was short on detail, although the board tried to be more intimidating by threatening to launch an investigation if it decided a manufacturer’s list price wasn’t low enough.

By focusing on mandating prices, rather than assessing whether they are excessive, the PMPRB appeared to flout the Federal Court of Appeal’s unanimous decision in 2021 that “excessive pricing provisions in the Patent Act are directed at controlling patent abuse, not reasonable pricing, price-regulation or consumer protection at large.”

Today, federal Health Minister Jean-Yves Duclos and the Liberal government have wisely decided not to proceed with further changes to the PMPRB regulations. This shift has been criticized on several occasions in the news media, with the government accused of capitulating to the biopharmaceutical industry. Politicians have made similar allegations.

This insinuation was also made several weeks ago in PMPRB member Matthew Herder’s resignation letter. Joining the chorus were former board chair Mitchell Levine and, in these pages, Ms. Philpott, criticizing what they see as a lack of resolve in the federal government.

But the withdrawal of the proposed changes was not a case of acquiescing to the industry. It happened because the PMPRB and its staff’s apparent hostility to the industry was unconstitutional.

In his letter, Mr. Herder praised the integrity and expertise of PMPRB staff. However, their integrity and impartiality are questionable when freedom of information requests reveal the board and its staff’s disrespect for the drug developers they regulate, stating that the industry is putting “profits first and patients a distant second,” and “has been sucking Canada for decades.”

The resignation letter of Mélanie Bourassa Forcier, the board’s acting chair, was also revealing. She wrote, as translated from French, that there is a “dialogue of the deaf that has been going on for years between the pharmaceutical industry and the PMPRB, which has resulted in costly legal proceedings for Canadians that could have been avoided.” Her ideas to re-examine pricing policy and methods and her “concerns about the legality of part of the reform” were ignored by the board.

The PMPRB has outlived its usefulness and should be disbanded. If it is to remain, the federal government must clean it out. In February, Thomas Digby, an intellectual-property lawyer with more than 25 years of experience working with the pharmaceutical sector, was appointed as the board’s new chair. This may be a step in the right direction, but that remains to be seen.

Everyone would like drugs to be cheaper, but not at the expense of having pharmaceutical companies and their innovative medicines bypass Canada. Several adversarial barriers to launching novel medicines already exist in this country, and Canadians don’t need additional anti-industry zealotry from their own federal agencies to deter developers. Without a collaborative relationship between manufacturers and governments, Canadians with unmet health needs will continue to suffer.

Nigel Rawson is an affiliate scholar with the Canadian Health Policy Institute and a senior fellow with the Macdonald-Laurier Institute.

Source: The Globe and Mail
Tags: domestic policyhealth careNigel Rawson
Previous Post

Deficit spending is the root of today’s bank failures: Jack Mintz in the Financial Post

Next Post

Oaths, trust and Canadian democracy: Stephen Van Dine and Karl Salgo for Inside Policy

Related Posts

Ukraine must be victorious, for all of our sakes: Balkan Devlen for Inside Policy
Columns

Ukraine’s right to self-defence is self-evident: Chris Alexander in the Globe and Mail

June 2, 2023
Trudeau, Ford to blame for Stellantis shakedown: Aaron Wudrick in the National Post
Columns

Trudeau, Ford to blame for Stellantis shakedown: Aaron Wudrick in the National Post

June 2, 2023
Canada’s inadequate defence research funding is more than just a security risk: Richard Shimooka in the Hub
Columns

Canada’s inadequate defence research funding is more than just a security risk: Richard Shimooka in the Hub

June 1, 2023
Next Post
Oaths, trust and Canadian democracy: Stephen Van Dine and Karl Salgo for Inside Policy

Oaths, trust and Canadian democracy: Stephen Van Dine and Karl Salgo for Inside Policy

Newsletter Signup

Follow us on

Macdonald-Laurier Institute

323 Chapel Street, Suite #300
Ottawa, Ontario, K1N 7Z2 Canada

613.482.8327

info@macdonaldlaurier.ca
MLI directory

Support Us

Support the Macdonald-Laurier Institute to help ensure that Canada is one of the best governed countries in the world. Click below to learn more or become a sponsor.

Support Us

  • Inside Policy Magazine
  • Annual Reports
  • Jobs
  • Privacy Policy

© 2021 Macdonald-Laurier Institute. All Rights reserved.

No Result
View All Result
  • Home
  • About
    • Who We Are
    • Who Makes MLI Work
    • Tenth Anniversary
  • Experts
    • Experts Directory
    • In Memoriam
  • Issues
    • Domestic Policy Program
      • Agriculture and Agri-Food
      • Canada’s Political Tradition
      • Economic policy
      • Health Care
      • Innovation
      • Justice
      • Social issues
      • Telecoms
    • Energy Policy Program
      • Energy
      • Environment
    • Foreign Policy Program
      • Foreign Affairs
      • National Defence
      • National Security
    • Indigenous Affairs Program
  • Projects
    • The Great Energy Crisis
    • Centre for Advancing Canada’s Interests Abroad
    • Dragon at the Door
    • Canada and the Indo-Pacific Initiative
    • The Transatlantic Program
    • DisInfoWatch.org
    • An Intellectual Property Strategy for Canada
    • Competition Policy in Canada
    • Speak for Ourselves
    • Justice Report Card
    • COVID Misery Index
      • Provincial COVID Misery Index
      • Beyond Lockdown
      • COVID and after: A mandate for recovery
    • Indigenous Prosperity at a Crossroads
      • Aboriginal Canada and Natural Resources
    • Past Projects
      • The Eavesdropping Dragon: Huawei
      • Talkin’ in the Free World with Mariam Memarsadeghi
      • Munk Senior Fellows
      • A Mandate for Canada
      • Confederation Series
      • Fiscal Reform
      • The Canadian Century project
      • Fixing Canadian health care
      • Internal trade
      • From a mandate for change
      • Size of government in Canada
      • Straight Talk
      • Labour Market Report
      • Leading Economic Indicator
  • Events
    • Upcoming Events
    • Past Events
      • MLI Dinners
      • Great Canadian Debates
  • Latest News
  • Libraries
    • Inside Policy Magazine
      • Inside Policy Online
      • Inside Policy Back Issues
    • Papers
    • Commentary
    • Columns
    • Books
    • Video
    • Podcasts

© 2021 Macdonald-Laurier Institute. All Rights reserved.